TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
TRDA

Entrada Therapeutics Inc

Healthcare · Biotechnology · —

6.20$ -4.3% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Balance Sheet TRDA
Line item 2019 2020 2021 2022 2023 2024 2025
– +138.7% +602.6% -17.6% +86.1% +12.2% -28.3%
– +129.1% +647.7% -29.7% +76.2% +19.0% -30.4%
– +131.8% +645.5% -84.5% +49.7% +49.7% -10.7%
– +131.8% +645.5% -35.2% +86.5% +19.3% -29.6%
– – – – – -37.4% -30.0%
– – – – – – –
– +279.2% +106.2% +427.4% – – –
– +151.9% -91.6% +455.2% +474.2% -57.0% -27.0%
– +74.9% +100.0% +227.0% +622.7% -75.1% -38.1%
– – – – -5.9% -4.4% -45.3%
– +125.6% -55.9% +748.4% -45.3% +30.0% -46.3%
– – – -28.8% +14.0% +76.9% -28.6%
– – – – – – –
– +2,881.7% -0.1% +0.2% +5.6% +18.0% +6.1%

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?